<p>隨着全球市場調整貨幣政策和持續的人工智能熱潮，亞洲經濟正面臨一系列挑戰與機遇。中國股市受到國內流動性的支撐，而日本經濟則顯示出增長跡象，投資者越來越關注能夠在這些動態條件下蓬勃發展的中小型股票。識別有前景的公司通常需要評估其對技術進步和經濟變化的適應能力，使其成為該地區潛在的 “未被發現的瑰寶”。</p>
<h3>亞洲十大基本面強勁的未被發現的瑰寶</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>伊藤忠食品</td>
<td>NA</td>
<td>1.64%</td>
<td>15.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>許昌遠東驅動軸有限公司</td>
<td>NA</td>
<td>-13.99%</td>
<td>-30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>西松科技</td>
<td>NA</td>
<td>1.35%</td>
<td>-9.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>泰順企業</td>
<td>0.03%</td>
<td>5.34%</td>
<td>7.18%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>深圳通業科技有限公司</td>
<td>11.85%</td>
<td>16.14%</td>
<td>-6.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>瀋陽遠大智能產業集團有限公司</td>
<td>NA</td>
<td>10.58%</td>
<td>33.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>東方精密與工程有限公司</td>
<td>34.33%</td>
<td>7.40%</td>
<td>2.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>DYPNF 有限公司</td>
<td>26.11%</td>
<td>13.24%</td>
<td>0.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>廣東三和樁</td>
<td>75.26%</td>
<td>-3.96%</td>
<td>-36.19%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>38.15%</td>
<td>4.63%</td>
<td>-6.91%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲基本面強勁的未被發現的瑰寶篩選器中的 2402 只股票的完整列表。</p>
<p>讓我們深入探討篩選器中的一些優質選擇。</p>
<h2>常州朗博密封科技有限公司 (SHSE:603655)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 常州朗博密封科技有限公司 (SHSE:603655) 專注於密封產品和組件的生產，市值為 48.7 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過製造業產生收入，金額為 2.2456 億人民幣。</p>
<p>朗博密封科技作為汽車零部件行業的靈活參與者，過去一年表現出 51.9% 的顯著盈利增長，超過行業的 2.3%。2025 年上半年收入達到 1.2184 億人民幣，較去年 1.0323 億人民幣有所增長，淨收入從 1204 萬人民幣上升至 1928 萬人民幣，儘管過去五年年均盈利下降 2.2%，但其似乎仍有持續增長的勢頭。沒有負債提供了財務靈活性；然而，近期股價波動和 610 萬人民幣的顯著一次性收益表明，未來需要謹慎監控。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解常州朗博密封科技有限公司的動態。</li>
<li>瞭解常州朗博密封科技有限公司的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aa46be72-73ba-4f36-b8ac-92e8c812f5c0/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aa46be72-73ba-4f36-b8ac-92e8c812f5c0/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 SHSE:603655 負債權益比</p>
<h2>無錫振華汽車零部件有限公司 (SHSE:605319)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 無錫振華汽車零部件有限公司在中國製造和銷售汽車零部件，市值為 92.5 億人民幣。</p>
<p><strong>運營：</strong> 該公司通過在中國製造和銷售汽車零部件產生收入，市值為 92.5 億人民幣。</p>
<p>無錫振華汽車零部件作為汽車零部件行業的有前景參與者，表現穩健。過去一年，該公司的盈利增長了 22%，超過行業的 2.3%。其淨負債權益比為 28.9%，利息支付由 EBIT 以 20.6 倍的覆蓋率良好覆蓋。最近報告的半年銷售額達到 12.2 億人民幣，較去年 10.6 億人民幣有所上升，淨收入為 2.01 億人民幣，較之前的 1.58 億人民幣有所增長。以僅 22 倍的市盈率相比於中國市場平均 45 倍，提供了吸引投資者在亞洲動態市場中尋求增長的價值潛力。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解無錫振華汽車零部件有限公司的表現。</li>
<li>查看我們的歷史表現報告，以獲取無錫振華汽車零部件有限公司的過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b1d3b7a3-9d3a-41e4-a506-4a5872b1a966/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b1d3b7a3-9d3a-41e4-a506-4a5872b1a966/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SHSE:605319 盈利和收入增長</p>
<h2>畢得醫藥 (SHSE:688073)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 畢得醫藥有限公司在中國從事藥品的研究、開發、生產和銷售，市值為 64.5 億人民幣。</p>
<p><strong>運營：</strong> 畢得醫藥主要通過研究和開發行業產生收入，金額為 12 億人民幣。</p>
<p>畢得醫藥最近的表現突顯了其在製藥行業的強勁地位，過去一年盈利增長 79.1%，顯著超過行業平均的-0.8%。該公司報告 2025 年上半年淨收入為 7341 萬人民幣，較去年 5184 萬人民幣有所上升，同時銷售額從 532.2 百萬人民幣上升至 627.53 百萬人民幣。儘管近期股價波動，畢得今年回購了價值 9999 萬人民幣的股份，反映出對其估值和未來前景的信心，預計年盈利增長為 21.28%。</p>
<ul>
<li>點擊這裏深入瞭解畢得醫藥的具體情況，查看我們的詳細健康報告。</li>
<li>通過我們的歷史報告獲取畢得醫藥的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd89aae6-cc4a-4bcd-a11f-dd1dfa24ee7b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd89aae6-cc4a-4bcd-a11f-dd1dfa24ee7b/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SHSE:688073 盈利和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接深入瞭解我們亞洲未被發現的基本面強勁的 2402 家公司。</li>
<li>這些公司中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的發展情況。</li>
<li>Simply Wall St 是你解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用程序。</li>
</ul>
<h2>對其他可能性感興趣嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

無錫振華

畢得醫藥

<p>隨着全球市場適應不斷變化的貨幣政策和人工智能的繁榮，亞洲經濟面臨着挑戰和機遇。投資者正將目光聚焦於小型股，特別是在中國和日本。文章強調了十傢俱有強大基本面的有前景的公司，包括常州朗博密封科技、無錫振華汽車零部件和畢得醫藥，展示了它們的財務表現和增長潛力。這些公司被視為該地區的 “未被發現的瑰寶”，吸引着尋求在動態市場中獲得增長的投資者</p>

<p>As global markets adjust to shifting monetary policies and the ongoing AI boom, Asian economies are experiencing a mix of challenges and opportunities. With China's stock markets buoyed by domestic liquidity and Japan's economy showing signs of growth, investors are increasingly looking for small-cap stocks that can thrive amid these dynamic conditions. Identifying promising companies often involves assessing their adaptability to technological advancements and economic shifts, making them potential &#34;undiscovered gems&#34; in the region.</p>
<div class="lb-trans"><p>隨着全球市場調整貨幣政策和持續的人工智能熱潮，亞洲經濟正面臨一系列挑戰與機遇。中國股市受到國內流動性的支撐，而日本經濟則顯示出增長跡象，投資者越來越關注能夠在這些動態條件下蓬勃發展的中小型股票。識別有前景的公司通常需要評估其對技術進步和經濟變化的適應能力，使其成為該地區潛在的 “未被發現的瑰寶”。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In Asia</h3>
<div class="lb-trans"><h3>亞洲十大基本面強勁的未被發現的瑰寶</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITOCHU-SHOKUHIN</td>
<td>NA</td>
<td>1.64%</td>
<td>15.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xuchang Yuandong Drive ShaftLtd</td>
<td>NA</td>
<td>-13.99%</td>
<td>-30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saison Technology</td>
<td>NA</td>
<td>1.35%</td>
<td>-9.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Taisun Enterprise</td>
<td>0.03%</td>
<td>5.34%</td>
<td>7.18%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shenzhen Tongye TechnologyLtd</td>
<td>11.85%</td>
<td>16.14%</td>
<td>-6.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shenyang Yuanda Intellectual Industry GroupLtd</td>
<td>NA</td>
<td>10.58%</td>
<td>33.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Oriental Precision &amp; EngineeringLtd</td>
<td>34.33%</td>
<td>7.40%</td>
<td>2.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>DYPNFLtd</td>
<td>26.11%</td>
<td>13.24%</td>
<td>0.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Guangdong Sanhe Pile</td>
<td>75.26%</td>
<td>-3.96%</td>
<td>-36.19%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>38.15%</td>
<td>4.63%</td>
<td>-6.91%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>伊藤忠食品</td>
<td>NA</td>
<td>1.64%</td>
<td>15.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>許昌遠東驅動軸有限公司</td>
<td>NA</td>
<td>-13.99%</td>
<td>-30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>西松科技</td>
<td>NA</td>
<td>1.35%</td>
<td>-9.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>泰順企業</td>
<td>0.03%</td>
<td>5.34%</td>
<td>7.18%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>深圳通業科技有限公司</td>
<td>11.85%</td>
<td>16.14%</td>
<td>-6.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>瀋陽遠大智能產業集團有限公司</td>
<td>NA</td>
<td>10.58%</td>
<td>33.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>東方精密與工程有限公司</td>
<td>34.33%</td>
<td>7.40%</td>
<td>2.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>DYPNF 有限公司</td>
<td>26.11%</td>
<td>13.24%</td>
<td>0.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>廣東三和樁</td>
<td>75.26%</td>
<td>-3.96%</td>
<td>-36.19%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>38.15%</td>
<td>4.63%</td>
<td>-6.91%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 2402 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲基本面強勁的未被發現的瑰寶篩選器中的 2402 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of from the screener.</p>
<div class="lb-trans"><p>讓我們深入探討篩選器中的一些優質選擇。</p>
</div><h2>Changzhou Langbo Sealing TechnologiesLtd (SHSE:603655)</h2>
<div class="lb-trans"><h2>常州朗博密封科技有限公司 (SHSE:603655)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Changzhou Langbo Sealing Technologies Ltd (SHSE:603655) specializes in the production of sealing products and components, with a market cap of CN¥4.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 常州朗博密封科技有限公司 (SHSE:603655) 專注於密封產品和組件的生產，市值為 48.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the manufacturing industry, amounting to CN¥224.56 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過製造業產生收入，金額為 2.2456 億人民幣。</p>
</div><p>Langbo Sealing Technologies, a nimble player in the auto components sector, has demonstrated impressive earnings growth of 51.9% over the past year, outpacing the industry's 2.3%. With revenue reaching CN¥121.84 million for H1 2025, up from CN¥103.23 million last year, and net income climbing to CN¥19.28 million from CN¥12.04 million, it seems poised for continued momentum despite historical earnings decline of 2.2% annually over five years. The absence of debt offers financial flexibility; however, recent volatility in share price and a notable one-off gain of CN¥6.1M suggest careful monitoring is warranted moving forward.</p>
<div class="lb-trans"><p>朗博密封科技作為汽車零部件行業的靈活參與者，過去一年表現出 51.9% 的顯著盈利增長，超過行業的 2.3%。2025 年上半年收入達到 1.2184 億人民幣，較去年 1.0323 億人民幣有所增長，淨收入從 1204 萬人民幣上升至 1928 萬人民幣，儘管過去五年年均盈利下降 2.2%，但其似乎仍有持續增長的勢頭。沒有負債提供了財務靈活性；然而，近期股價波動和 610 萬人民幣的顯著一次性收益表明，未來需要謹慎監控。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Changzhou Langbo Sealing TechnologiesLtd.</li>
<li>Learn about Changzhou Langbo Sealing TechnologiesLtd's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解常州朗博密封科技有限公司的動態。</li>
<li>瞭解常州朗博密封科技有限公司的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aa46be72-73ba-4f36-b8ac-92e8c812f5c0/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/aa46be72-73ba-4f36-b8ac-92e8c812f5c0/chart/debt-equity-history-analysis"/></p>
<p>SHSE:603655 Debt to Equity as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:603655 負債權益比</p>
</div><h2>Wuxi Zhenhua Auto PartsLtd (SHSE:605319)</h2>
<div class="lb-trans"><h2>無錫振華汽車零部件有限公司 (SHSE:605319)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Wuxi Zhenhua Auto Parts Co., Ltd. manufactures and sells auto parts in China with a market cap of CN¥9.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 無錫振華汽車零部件有限公司在中國製造和銷售汽車零部件，市值為 92.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue from manufacturing and selling auto parts in China. It has a market capitalization of CN¥9.25 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過在中國製造和銷售汽車零部件產生收入，市值為 92.5 億人民幣。</p>
</div><p>Wuxi Zhenhua Auto Parts, a promising player in the auto components sector, has demonstrated solid performance. The company's earnings grew by 22% over the past year, outpacing the industry's 2.3%. Its net debt to equity ratio stands at a satisfactory 28.9%, with interest payments well covered by EBIT at 20.6 times coverage. Recently reported half-year sales reached CNY 1.22 billion, up from CNY 1.06 billion last year, while net income hit CNY 201 million compared to CNY 158 million previously. With a price-to-earnings ratio of just 22x against the CN market's average of 45x, it offers attractive value potential for investors seeking growth in Asia's dynamic markets.</p>
<div class="lb-trans"><p>無錫振華汽車零部件作為汽車零部件行業的有前景參與者，表現穩健。過去一年，該公司的盈利增長了 22%，超過行業的 2.3%。其淨負債權益比為 28.9%，利息支付由 EBIT 以 20.6 倍的覆蓋率良好覆蓋。最近報告的半年銷售額達到 12.2 億人民幣，較去年 10.6 億人民幣有所上升，淨收入為 2.01 億人民幣，較之前的 1.58 億人民幣有所增長。以僅 22 倍的市盈率相比於中國市場平均 45 倍，提供了吸引投資者在亞洲動態市場中尋求增長的價值潛力。</p>
</div><ul>
<li>Get an in-depth perspective on Wuxi Zhenhua Auto PartsLtd's performance by reading our health report here.</li>
<li>Review our historical performance report to gain insights into Wuxi Zhenhua Auto PartsLtd's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解無錫振華汽車零部件有限公司的表現。</li>
<li>查看我們的歷史表現報告，以獲取無錫振華汽車零部件有限公司的過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b1d3b7a3-9d3a-41e4-a506-4a5872b1a966/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b1d3b7a3-9d3a-41e4-a506-4a5872b1a966/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:605319 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:605319 盈利和收入增長</p>
</div><h2>Bide Pharmatech (SHSE:688073)</h2>
<div class="lb-trans"><h2>畢得醫藥 (SHSE:688073)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Bide Pharmatech Co., Ltd. is involved in the research, development, production, and sale of pharmaceutical products in China with a market capitalization of CN¥6.45 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 畢得醫藥有限公司在中國從事藥品的研究、開發、生產和銷售，市值為 64.5 億人民幣。</p>
</div><p><strong>Operations:</strong> Bide Pharmatech generates revenue primarily from the research and development industry, amounting to CN¥1.20 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 畢得醫藥主要通過研究和開發行業產生收入，金額為 12 億人民幣。</p>
</div><p>Bide Pharmatech's recent performance highlights its strong position in the pharmaceutical sector, with earnings growth of 79.1% over the past year, significantly outpacing the industry average of -0.8%. The company reported a net income of CNY 73.41 million for the first half of 2025, up from CNY 51.84 million last year, alongside sales rising to CNY 627.53 million from CNY 532.2 million previously. Despite a volatile share price recently, Bide has repurchased shares worth CNY 99.99 million this year, reflecting confidence in its valuation and future prospects as it forecasts annual earnings growth at 21.28%.</p>
<div class="lb-trans"><p>畢得醫藥最近的表現突顯了其在製藥行業的強勁地位，過去一年盈利增長 79.1%，顯著超過行業平均的-0.8%。該公司報告 2025 年上半年淨收入為 7341 萬人民幣，較去年 5184 萬人民幣有所上升，同時銷售額從 532.2 百萬人民幣上升至 627.53 百萬人民幣。儘管近期股價波動，畢得今年回購了價值 9999 萬人民幣的股份，反映出對其估值和未來前景的信心，預計年盈利增長為 21.28%。</p>
</div><ul>
<li>Dive into the specifics of Bide Pharmatech here with our thorough health report.</li>
<li>Gain insights into Bide Pharmatech's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解畢得醫藥的具體情況，查看我們的詳細健康報告。</li>
<li>通過我們的歷史報告獲取畢得醫藥的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd89aae6-cc4a-4bcd-a11f-dd1dfa24ee7b/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/dd89aae6-cc4a-4bcd-a11f-dd1dfa24ee7b/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688073 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:688073 盈利和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Click this link to deep-dive into the 2402 companies within our Asian Undiscovered Gems With Strong Fundamentals screener.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們亞洲未被發現的基本面強勁的 2402 家公司。</li>
<li>這些公司中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的發展情況。</li>
<li>Simply Wall St 是你解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用程序。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

探索 2025 年 9 月亞洲未被發現的珍寶